Diamyd Medical AB (publ)

Stockholm Stock Exchange DMYD-B.ST

Diamyd Medical AB (publ) EBIT for the year ending August 31, 2024: USD -14.80 M

Diamyd Medical AB (publ) EBIT is USD -14.80 M for the year ending August 31, 2024, a -40.50% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Diamyd Medical AB (publ) EBIT for the year ending August 31, 2023 was USD -10.53 M, a -12.43% change year over year.
Diamyd Medical AB (publ) EBIT for the year ending August 31, 2022 was USD -9.37 M, a 5.79% change year over year.
Diamyd Medical AB (publ) EBIT for the year ending August 31, 2021 was USD -9.94 M, a -157.89% change year over year.
Diamyd Medical AB (publ) EBIT for the year ending August 31, 2020 was USD -3.85 M, a -4.19% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Stockholm Stock Exchange: DMYD-B.ST

Diamyd Medical AB (publ)

CEO	Mr. Ulf Hannelius MBA, Ph.D.
IPO Date	May 20, 2013
Location	Sweden
Headquarters	Kungsgatan 29
Employees	27
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Vaccines

Description

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.

Key trends

Past 5 years